Close menu




May 6th, 2025 | 07:05 CEST

Soil boosters wanted! The secret weapons of Bayer, Argo Living Soils, and K+S

  • Pharma
  • fertilizer
  • Agriculture
  • Technology
Photo credits: pixabay.com

Agriculture is at a crossroads between tradition and revolution. While optimistic forecasts like the Iowa Crop Progress Report 2025 predict record-breaking harvests, a paradoxical conflict is emerging. Blooming fields conceal depleting soils and climate stress. But this is precisely where the tension for innovation unfolds - where high-tech meets sustainability. Three players are helping to shape this future: Bayer as a pioneer of digital agricultural solutions; Argo Living Soils with revolutionary soil savers; and K+S, which is rethinking mineral fertilizers. Together, they are not only securing harvests but also healing ecosystems.

time to read: 5 minutes | Author: Armin Schulz
ISIN: BAYER AG NA O.N. | DE000BAY0017 , ARGO LIVING SOILS CORP | CA04018T3064 , K+S AG NA O.N. | DE000KSAG888

Table of contents:


    Bayer – Repositioning in a turbulent environment

    The Leverkusen-based chemical and pharmaceutical giant Bayer is undergoing a period of strategic change. Following a disappointing 2024 financial year with stagnating sales of EUR 46.6 billion and declining earnings, the Crop Science division is becoming the focus of restructuring efforts. The division, which generates almost half of the Company's sales, is struggling with regulatory hurdles, including the withdrawal of dicamba approval in the US in 2024 and price pressure on seeds. At the same time, legal disputes over glyphosate-containing products are dragging on. Bayer has now appealed to the US Supreme Court to overturn lawsuits alleging warning label deficiencies under federal law.

    To boost its flagging profitability, Bayer is focusing on a five-year plan through 2029. The plan calls for additional revenue of EUR 3.5 billion through new seed generations, such as the high-yielding "Super Seeds," and precision solutions in crop protection. At the same time, portfolio streamlining and cost efficiency are being pushed forward, for example, by cutting 7,000 jobs. Despite regional differences, such as the recovery in Latin America while North America recorded a decline, the EBITDA margin is expected to rise to over 20% by 2029. Digital tools and regenerative farming methods complement the program to retain farmers in the long term.

    At the virtual shareholders' meeting, CEO Bill Anderson emphasized the progress made. Net debt fell to EUR 32.6 billion in 2024, while free cash flow rose to EUR 3.1 billion. However, sales are expected to stagnate again in 2025, with sustainable growth not expected to begin until 2026. As a safety buffer, the Company requested a capital increase option of up to 35%. At the same time, Bayer is pushing ahead with cutting bureaucracy. The number of hierarchical levels has been reduced from 12 to 6. If the balance between legal risk minimization and innovative strength can be achieved, Crop Science could become the decisive factor in the turnaround. The share price currently stands at EUR 24.00.

    Argo Living Soils – Research alliance for climate-friendly concrete

    Argo Living Soils is a Canadian specialist in ecological solutions for soil improvers, living soils, and biofertilizers. Its focus is on converting biomass into multifunctional materials. When plant residues such as wood waste or plant residues are decomposed under heat without oxygen, biochar is produced. This porous carbon material improves soil quality in agriculture by storing water and nutrients. The material can also be used as an additive in asphalt to increase its heat resistance or as a hydrogen storage medium in energy systems. In addition, the Company is developing methods to synthesize graphene from the biochar obtained, for example, through high-temperature or liquid processes. This dual strategy closes cycles and opens up new markets.

    This has also led to cooperation with Graphene Leaders Canada (GLC), a leading carbon technology provider. The goal is to develop graphene nanoplatelets (GNP) as an additive for ready-mixed concrete. Studies show that such additives can increase the compressive strength of the building material by up to 30%, improve its durability against environmental influences, and reduce CO2 emissions by 20% through reduced cement requirements. The North American market for concrete, currently worth USD 250 billion, is growing by 4.5% annually, driven by infrastructure projects and sustainability requirements. The partnership aims to develop a proof-of-concept formulation by the end of 2025, which will be validated in independent laboratory tests.

    As part of the three-month Phase 1 initiative, GLC is providing CAD 100,000 for the development of prototype concrete mixes with GNP. The collaboration combines expertise in graphene processing with know-how in sustainable material innovations. Successful tests could pave the way for industrial applications – a relevant lever in an industry responsible for 8% of global emissions. For investors, the project highlights not only technological agility but also the ability to leverage synergies between the agriculture and construction sectors. In the long term, the Company will position itself as a bridge builder in the green transformation. The share price broke out of its sideways phase last Friday and is currently trading at CAD 0.58.

    K+S – Strategic realignment and robust quarterly figures

    As a global player in fertilizer and salt production, K+S combines traditional industry with modern agriculture. With 11,500 employees and locations on two continents, the Company not only supplies winter services with de-icing salt but also supports food production with mineral nutrients. The Company is currently focusing more strongly on specialty fertilizers and digital efficiency improvements. At the same time, it emphasizes its responsibility for sustainable business practices – a balancing act between profitability and ecological considerations.

    The first quarter brought unexpected tailwinds for K+S. EBITDA of EUR 201 million exceeded analyst estimates by 15%, while adjusted free cash flow of EUR 32 million was three times higher than forecast. This was driven by higher potash prices in agricultural markets and cost savings. In response, management raised its EBITDA target range for 2025 to EUR 560–640 million. Despite rising working capital requirements, the Company is now even signaling a slightly positive free cash flow for the full year.

    The recent approval for two new mining fields in the Lower Rhine region secures salt production in Borth for at least 25 years. Transparent dialogue with local authorities and stricter environmental requirements – including 3D terrain models and expanded monitoring – have resulted in a socially acceptable solution. The deposits south of Xanten and near Alpen are expected to supply high-purity pharmaceutical and food-grade salt while minimizing subsidence risks. For investors, this underscores the Company's long-term raw material base. The share price has been on the rise since the beginning of April. A share currently costs EUR 15.43.


    Agriculture is undergoing a transformation amid the conflicting demands of high-tech and ecology. Despite regulatory turmoil and stagnating revenues, Bayer is focusing on digital agricultural solutions and "super seeds" to revamp its struggling Crop Science division. Argo Living Soils is revolutionizing not only agriculture but also the construction sector with biochar and a graphene partnership by optimizing CO2-intensive concrete and making it more climate-friendly. K+S is stabilizing its finances thanks to higher fertilizer prices and sustainable salt production, while minimizing ecological risks. Together, the three companies are demonstrating how innovations in soil management can secure harvests and regenerate ecosystems – a crucial response to dwindling resources and climate stress.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Fabian Lorenz on October 17th, 2025 | 07:15 CEST

    Acquisition of Vidac Pharma and Evotec? USD 400 billion at stake for Pfizer, Merck & Co!

    • Biotechnology
    • Biotech
    • Pharma

    Alarm bells are ringing in Big Pharma! Donald Trump appears serious about reducing drug prices. At the same time, patents on blockbuster drugs are expiring, threatening a USD 400 billion revenue shortfall. Pfizer, Merck, and Co. must refill their pipelines. The acquisition merry-go-round is expected to spin even faster in the coming years. Among the potential takeover targets is Vidac Pharma. The Company is still attractively priced, but if its new approach to fighting cancer proves successful in early clinical trials, a multiplication could be possible. And what about Evotec? The Hamburg-based company has repeatedly been traded as a takeover candidate in recent years. However, data and patents are offset by internal problems.

    Read

    Commented by Armin Schulz on October 16th, 2025 | 07:20 CEST

    Investors take note: BioNxt Solutions builds on blockbusters from Novo Nordisk and Merck - and has another ace up its sleeve in oncology

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • blockbuster
    • Technology

    In the biotech sector, a single technology can often determine success or failure. Canadian-German company BioNxt Solutions is taking a different approach, relying on three pillars, each targeting major markets and advancing established blockbusters from leading pharmaceutical companies. October has already brought decisive progress, from accelerated patent protection to concrete milestones in development. These concentrated positive signals show that BioNxt Solutions not only has a promising concept, but also the strategy and operational strength to turn it into value. A closer analysis is worthwhile.

    Read

    Commented by André Will-Laudien on October 15th, 2025 | 08:30 CEST

    Correction and high volatility- Triple AAA is the order of the day: Amazon, Aspermont, and Alibaba keep their promises!

    • Digitization
    • ecommerce
    • rawmaterials
    • bigdata
    • Technology

    A lot is happening right now — up and down, left and right! Stock markets have become increasingly volatile, reacting to the latest political statements, especially those from US President Donald Trump. While the crypto world is experiencing a sharp correction, investors are once again turning to precious metals and critical raw materials. Aspermont is an expert in raw materials. The Company has been building its network for several decades – now the harvest phase seems to be starting. Amazon and Alibaba have already launched their Black Friday sales this year, but the big shopping event kicks off with Thanksgiving. We take a closer look at profitable business models and strong stocks that are well-positioned to weather the next storm!

    Read